Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2019 1
2020 2
2021 5
2022 2
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.
Luterbach CL, Qiu H, Hanafin PO, Sharma R, Piscitelli J, Lin FC, Ilomaki J, Cober E, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, Nation RL, Bonomo RA, Landersdorfer CB, van Duin D, Rao GG; Antibacterial Resistance Leadership Group. Luterbach CL, et al. Among authors: hanafin po. Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0059122. doi: 10.1128/aac.00591-22. Epub 2022 Sep 20. Antimicrob Agents Chemother. 2022. PMID: 36125299 Free PMC article.
A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients.
Hanafin PO, Kwa A, Zavascki AP, Sandri AM, Scheetz MH, Kubin CJ, Shah J, Cherng BPZ, Yin MT, Wang J, Wang L, Calfee DP, Bolon M, Pogue JM, Purcell AW, Nation RL, Li J, Kaye KS, Rao GG. Hanafin PO, et al. Clin Microbiol Infect. 2023 Sep;29(9):1174-1181. doi: 10.1016/j.cmi.2023.05.018. Epub 2023 May 20. Clin Microbiol Infect. 2023. PMID: 37217076
Pharmacokinetic Considerations for Optimizing Inhaled Spray-Dried Pyrazinoic Acid Formulations.
Yeshwante SB, Hanafin P, Miller BK, Rank L, Murcia S, Xander C, Annis A, Baxter VK, Anderson EJ, Jermain B, Konicki R, Schmalstig AA, Stewart I, Braunstein M, Hickey AJ, Rao GG. Yeshwante SB, et al. Among authors: hanafin p. Mol Pharm. 2023 Sep 4;20(9):4491-4504. doi: 10.1021/acs.molpharmaceut.3c00199. Epub 2023 Aug 17. Mol Pharm. 2023. PMID: 37590399
Pharmacokinetic considerations for optimizing inhaled spray-dried pyrazinoic acid formulations.
Yeshwante SB, Hanafin P, Miller BK, Rank L, Murcia S, Xander C, Annis A, Baxter VK, Anderson EJ, Jermain B, Konicki R, Schmalstig AA, Stewart I, Braunstein M, Hickey AJ, Rao GG. Yeshwante SB, et al. Among authors: hanafin p. bioRxiv [Preprint]. 2023 Apr 3:2023.04.01.534965. doi: 10.1101/2023.04.01.534965. bioRxiv. 2023. PMID: 37066292 Free PMC article. Updated. Preprint.
Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety.
Lee E, Gibbs JP, Emery MG, Block G, Wasserman SM, Hamilton L, Kasichayanula S, Hanafin P, Somaratne R, Egbuna O. Lee E, et al. Among authors: hanafin p. Clin Pharmacol Drug Dev. 2019 Apr;8(3):281-289. doi: 10.1002/cpdd.650. Epub 2019 Jan 24. Clin Pharmacol Drug Dev. 2019. PMID: 30676701 Free PMC article.
16 results